Novo took its message to the people by setting up an exhibit at New York’s Grand Central Terminal. In a major thoroughfare at the commuter rail terminal, Novo invited people to explore three dimensions of the obesity trap. The exhibit ran from Jan. 5 to Jan. 7.

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x

Novo Nordisk A/S is rated Buy with Wegovy pill seen as a potential catalyst to reignite growth & recapture market share. Read more on NVO stock here.

Novo Nordisk (NVO) concluded the recent trading session at $57.34, signifying a +1.36% move from its prior day's close.

Novo Nordisk is trying to get back on track in the U.S., but it just lost an important worker in Washington. An internal memo said that Jennifer Duck, who was in charge of U.S. public affairs for Novo Nordisk,

Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA approval, aggressive pricing, and first-mover advantage position NVO to regain market share and expand margins.

Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortunes in its top market.

TORONTO — Novo Nordisk Canada is considering competing with generic versions of its brand-name Ozempic and Wegovy drugs by introducing renamed, lower-priced copies of the medications. Health Canada approved the company’s submissions for Plosbrio and Poviztra on Dec. 22.